Volume 7 | March 8, 2023 | View in Browser
As we thank our 2022 MIB Agents Junior Advisory Board, and welcome our 2023 members, we are reminded about how critical patient perspective is for improving osteosarcoma clinical care. Our Junior Advisory Board, a group of young adults who either have lost a sibling to osteosarcoma or are OsteoWarriors themselves, is in many ways our north star, not only for MIB Agents initiatives and programs, but for our community, like pharmaceutical companies seeking patient input for communications and clinical trials. Patients and their families are also key partners in our OutSmarting grant process, not only funding the grants, but participating side by side with our scientific peer reviewers to provide input on patient impact. When MIB Agents recently visited our 2022 OutSmarting recipients in Denver and Atlanta, we conveyed the significance and urgency of the funded research by shining a light on the patients and families who are in crucial need of new treatments and have been impacted by this disease. By opening up the conversation to patients and making room for their voices, the osteosarcoma community is making huge strides. Patients can make their voice heard by participating in a global patient survey on bone sarcoma research priorities. They might not be able to talk, but dogs can make an impact too through our OutBarking Osteosarcoma fundraiser. And please check out the DOGBONe team is this issue, about how they are giving voice to their canine patients by collaborating on samples and canine osteosarcoma research.
With hope,
Ann
Join us June 22-24 at the Whitley Hotel in Atlanta for the 6th Annual FACTOR conference!
Register by March 15th to take advantage of the Early Bird discount!
Apply for a Family Fund FACTOR Travel Award - Due April 7th
The incidence rate of osteosarcoma is 10-50x higher in dogs than in humans. Groundbreaking osteosarcoma research in dogs will translate to better treatments for kids. OutBark Osteosarcoma with us! Order a fashion statement bandana for your doggie, snap a photo of your doggie rocking the bandana, and encourage your friends and family to vote for who wore it best! Voting ends on March 17 and winners will be announced on March 23 on National Puppy Day! Learn More
.png)
.jpeg)
.jpg)
Meet the DOGBONe group at the University of Guelph Ontario Veterinary College. Anthony J. Mutsaers DVM, PhD, DACVIM Oncology, Associate Professor at OVC shares with us the focus of the DOGBONe group, how the group came together, and how the group has evolved into an osteosarcoma multidisciplinary research team that shares samples, and is studying novel therapeutics for osteosarcoma.
If you have a job posting and you would like it included here, please email christina@mibagents.org.
.png)
Watch Past Episodes and See the Upcoming Schedule
.png)
A virtual tumor review board for osteosarcoma, TURBO is open to global clinicians or researchers with an interest in osteosarcoma. Patients and families are welcome to ask their oncologists to present a case on their behalf. Join TURBO to request an invite or submit a case.
Next meeting: March 8th at 5pm ET
Next meeting: May 10th at 5pm ET
MIB Agents has assisted many OS Warriors and their families by carefully matching them with osteosarcoma survivors and their families. We are always ready to help OS Warriors and their families to find an Ambassador Agent, who are devoted to helping their peers navigate life through osteosarcoma. Our next in-person training session for Ambassadors will take place at the Whitley Hotel in Atlanta on June 21st, the day before the official start of the MIB Agents FACTOR23 conference in Atlanta.
To learn more or to request an Ambassador Agent, contact isabel@mibagents.org
Sign Up for Ambassador Agent Training at FACTOR23
The patients and parents group in the FOSTER (Fight OSteosarcoma Through European Research) consortium are undertaking the first-ever global survey for bone sarcoma patients. Take the survey to have your voice heard and share your experiences and research priorities. The survey is open to all global bone sarcoma patients, survivors, and caregivers.
Access the MIB Agents clinical trials search powered by Antidote to find a clinical trial for osteosarcoma in 60 seconds.
If you have a trial that is currently enrolling osteosarcoma patients and you would like it included here, please email christina@mibagents.org.
